TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06441331: Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Sponsor: ITM Solucin GmbH · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,193,808

Rescue Site Savings

+$785,400

Unlock Full NCT06441331 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06441331 Rescue Dossier →